LYFE Capital

LYFE Capital operates from Shanghai as a healthcare-focused venture firm with a growth-stage orientation, investing in biotech, medical devices, and digital health. The firm’s positioning is shaped by check size: at twenty-five million dollars and above, LYFE Capital plays the role of a meaningful growth-round participant rather than an early company-formation investor. Activity in biotech and devices reflects depth in the kind of clinical-stage and commercial-stage healthcare investing that defines later rounds, while digital health exposure brings exposure to software-driven business models that have grown rapidly across Chinese healthcare markets. Limited public information is available about specific named partners and a fully disclosed portfolio in this profile, though the firm is established within Chinese healthcare growth investing.

Check sizes start at twenty-five million dollars, deployed at Series B, Series C, and growth stages. Geographic focus is centered on China, with the firm well positioned to participate in the larger rounds Chinese healthcare companies need as they approach commercial inflection. The fund’s scale and stage focus mean it is rarely a first venture investor but frequently a meaningful supporter of companies that have already established traction.

For founders, LYFE Capital is most relevant when a company is past Series A, has clinical or commercial validation, and needs the kind of capital that growth rounds in Chinese healthcare typically require. Expect a partner with experience navigating regulatory, clinical, and commercial milestones in China and a willingness to engage on growth-stage execution. Early-stage founders looking for first venture capital will find this the wrong stage match, while later-stage healthcare founders with meaningful traction will find a sector-aligned partner sized to participate at scale.